Mallinckrodt PLC | Key People and Executives
Angus C. Russell
Chairman
Mark C. Trudeau
President, Chief Executive Officer & Director
Anne Clem Whitaker
Director
David York Norton
Independent Director
David R. Carlucci
Independent Director
J. Martin Carroll
Independent Director
Kneeland C. Youngblood
Independent Director
Joseph A. Zaccagnino
Independent Director
JoAnn A. Reed
Independent Director
Angus C. Russell
Chairman
Mark C. Trudeau
President, Chief Executive Officer & Director
Frank Scholz
EVP-Global Operations & Digital Innovation Officer
Matthew K. Harbaugh
Chief Financial Officer & Executive Vice President
Steven Romano
Chief Scientific Officer & EVP
Tunde Otulana
Chief Medical Officer & Senior Vice President
Karen Sheehy
Chief Compliance Officer
Ron Lloyd
EVP & President-Hospital Therapies
B. Lynn Allen-Hoffmann
SVP-Regenerative Medicine
Daniel J. Speciale
Investor Relations & Strategy Officer
Dagmar Rosa-Bjorkeson
Chief Strategy & Corporate Development Officer
Hugh M. Oneill
President-Specialty Pharmaceuticals & Senior VP
Kathleen A. Schaefer
Vice President & Controller
Anne Clem Whitaker
Director
John E. Einwalter
Treasurer & Vice President
Marvin R. Haselhorst
Vice President-Global Tax
Meredith B. Fischer
Chief Public Affairs Officer
Ian J. Watkins
Chief Human Resources Officer
Stephanie D. Miller
Secretary & Vice President-International Legal
Mark J. Casey
General Counsel
David York Norton
Independent Director
David R. Carlucci
Independent Director
J. Martin Carroll
Independent Director
Kneeland C. Youngblood
Independent Director
Joseph A. Zaccagnino
Independent Director
JoAnn A. Reed
Independent Director
| Address |
3 Lotus Park
Staines-Upon-Thames Surrey TW18 3AG
United Kingdom
|
|
Employees
|
- |
| Website |
http://mallinckrodt.com |
| Updated |
07/08/2019 |
| Mallinckrodt Plc operates as a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. |
